Feedback / Questions
amelenodor (NX-13) - Landos Biopharma
NX-13: Topline data from P2 trial (NCT05785715) for moderate to severe ulcerative colitis in Q4 2024
(Landos Biopharma)
-
Apr 29, 2024 -
Corporate Presentation
P2 data
•
Inflammatory Bowel Disease • Ulcerative Colitis
https://ir.landosbiopharma.com/static-files/c99d4848-5216-4776-91f2-6a81e0cdf5b1
Apr 29, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious